Cargando…
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
[Image: see text] The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated. Current standard of care for VL suffers from multiple issues and there is a limited pipeline of new candidate drugs. As such, the...
Ejemplares similares
-
Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis
por: Thomas, Michael G., et al.
Publicado: (2020) -
Cyclin-dependent kinase 12, a novel drug target for visceral
leishmaniasis
por: Wyllie, Susan, et al.
Publicado: (2018) -
The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2013) -
Identification
and Optimization of a Series of 8-Hydroxy
Naphthyridines with Potent In Vitro Antileishmanial
Activity: Initial SAR and Assessment of In Vivo Activity
por: Thomas, Michael G., et al.
Publicado: (2020) -
Discovery of Indoline-2-carboxamide
Derivatives as
a New Class of Brain-Penetrant Inhibitors of Trypanosoma
brucei
por: Cleghorn, Laura A. T., et al.
Publicado: (2015)